**
Emerging evidence suggests that GLP-1 medications, commonly prescribed for weight management, may also lower the risk of certain cancers. This research arrives at a pivotal moment as semaglutide, a prominent GLP-1 drug, becomes increasingly available in Canadian pharmacies, with generic versions expected to reduce costs significantly. These findings were unveiled during the recent American Society of Clinical Oncology meeting held in Chicago, where over two dozen studies highlighted the potential benefits of GLP-1 medications in cancer prevention and treatment outcomes.
Transformative Potential of GLP-1 Drugs
Dr. Judith Bray, the vice-president of research at the Canadian Cancer Society, remarked on the significance of these findings, stating that they “have the potential to be transformative.” She noted that the scientific community has been buzzing with speculation about the connection between GLP-1 drugs and cancer outcomes for over a year. “Suddenly, the whole research world woke up,” she said, emphasising the importance of these recent studies.
One notable study presented by the ESMO Annals of Oncology analysed data from more than 161,000 patients, primarily aged 47, who were classified as obese but had not been diagnosed with diabetes or any obesity-related cancer. Participants were divided into two groups: one receiving GLP-1 injections while the other followed a diet and exercise consultation regimen. Astonishingly, those who were administered GLP-1s exhibited a 41 per cent reduction in the risk of being diagnosed with obesity-related cancer over the two-year follow-up period.
Breast Cancer Prevention Insights
Further research published on June 2 in the JCO Oncology Practice revealed a concerning yet promising association between GLP-1 therapy and breast cancer risk. This study focused on over 110,000 women aged 45 to 80 who underwent breast imaging between January 2022 and June 2025. Among these women, nearly 14 per cent had been prescribed GLP-1 medications.
The findings indicated that women using GLP-1 drugs had a 35 per cent lower risk of developing breast cancer compared to those who did not use these medications. To bolster these results, researchers matched over 15,000 women on GLP-1 therapy with counterparts who had similar backgrounds, leading to a further revelation that those on GLP-1s had nearly 31 per cent lower odds of breast cancer diagnosis.
Dr. Elizabeth McDonald, the lead researcher, cautioned that while the study was observational, it adds to the growing evidence warranting further investigation into GLP-1 medications as potential tools in cancer prevention strategies.
The Need for Further Research
Despite the promising outcomes, experts like Dr. Bray stress the necessity for more research. There remain unanswered questions regarding whether GLP-1 medications could also help in preventing cancer recurrence. “If someone has already had cancer, could these drugs delay or prevent the spread of the disease?” she pondered.
Statistics Canada reports a worrying trend: from 2022 to 2024, 68 per cent of Canadian adults aged 18 to 79 were classified as overweight or obese, a significant increase from 60 per cent before the pandemic. Given this context, the implications of GLP-1 drugs in cancer prevention could be monumental, especially as they gain traction among healthcare providers.
Kimberly Carson, CEO of Breast Cancer Canada, expressed optimism regarding the research, calling it “very encouraging” and emphasising the need for Canadian studies. “I’d love to see Canadian data on this,” she remarked, highlighting the opportunity for Canada to lead in this promising area of research.
Why it Matters
The potential link between GLP-1 medications and reduced cancer risk could represent a significant shift in preventative healthcare strategies. As obesity rates continue to rise in Canada, these findings not only underscore the multifaceted benefits of these medications but also pave the way for future research that could redefine cancer prevention. Such advancements could ultimately lead to improved health outcomes and a more proactive approach to tackling one of the most pressing health crises of our time.
